NDA 214662 · Mirum
Livmarli
Maralixibat Chloride · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Sep 29, 2021: To treat cholestatic pruritus associated with Alagille syndrome
Last checked: Nov 20, 2026Latest source record: Nov 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Sep 29, 2021
Approved uses
4
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 0 recruiting
FAERS reports
1,002
284 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 10, 2025.
LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for: • the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). ( 1.1 ) • the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.2 ) o Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. ( 14.2 ) 1.1 Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome LIVMARLI ® is indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). 1.2 Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis LIVMARLI is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein [see Clinical Studies (14.2) ] .
Mechanism: Maralixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by which maralixibat improves pruritus in ALGS or PFIC patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids [see Clinical...
Therapeutic areas: Rare and genetic disease · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2024 Supplement 10 · Efficacy OrphanLetterLabel
- Mar 13, 2024 Supplement 5 · Efficacy OrphanLetterLabel
- Mar 13, 2023 Supplement 4 · Efficacy · priority review OrphanLetterLabel
- Sep 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- LIVMARLI · MARALIXIBAT CHLORIDE EQ 9.5MG BASE/ML · SOLUTION, ORAL · Prescription
- LIVMARLI · MARALIXIBAT CHLORIDE EQ 19MG BASE/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Maralixibat Chloride" as an intervention, any sponsor and status, largest first.
Mirum Pharmaceuticals, Inc.Industry
NCT04168385 · 52 participants · Start Jan 16, 2020 · Primary completion Sep 4, 2024
Drug: Maralixibat · For: Cholestatic Liver Disease
Sites: Los Angeles, California; Indianapolis, Indiana; Philadelphia, Pennsylvania · 17 sites in all
Mirum Pharmaceuticals, Inc.Industry
NCT02160782 · 31 participants · Start Oct 28, 2014 · Primary completion May 28, 2020
Drug: LUM001 (Maralixibat); Placebo · For: Alagille Syndrome
Sites: Westmead, Australia; Parkville, Australia; Brussels, Belgium · 9 sites in all
Mirum Pharmaceuticals, Inc.Industry
NCT04729751 · 27 participants · Start Sep 9, 2021 · Primary completion Dec 17, 2024
Drug: Maralixibat · For: Progressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver Disease
Sites: Los Angeles, California; San Francisco, California; Washington D.C., District of Columbia · 14 sites in all
- A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05543174 · 7 participants · Start Jan 16, 2023 · Primary completion Oct 25, 2023
Drug: TAK-625 · For: Alagille Syndrome (ALGS)
Sites: Tsukuba, Japan; Yokohama, Japan; Sendai, Japan · 8 sites in all
- A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05543187 · 5 participants · Start Jan 10, 2023 · Primary completion Sep 4, 2023
Drug: TAK-625 · For: Progressive Familial Intrahepatic Cholestasis (PFIC)
Sites: Tsukuba, Japan; Yokohama, Japan; Tsuyama, Japan · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus258
- off label use120
- liver transplant103
- diarrhoea101
- drug ineffective83
- hepatic enzyme increased78
- alanine aminotransferase increased67
- blood bilirubin increased64
- aspartate aminotransferase increased59
- bile acids increased53
- jaundice44
- vomiting41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 336 |
| 2023 | 199 |
| 2024 | 147 |
| 2025 | 163 |
| 2026 | 155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Livmarli (Maralixibat Chloride)
2024 spending
$7.9M
Beneficiaries
n/a
64 claims
Per beneficiary
n/a
$1,829.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,784,094 |
| 2023 | $3,899,017 |
| 2024 | $7,900,834 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Mirum
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.